Acknowledgements
AMM, Cancer
CANCER, LUNG CANCER
Source of funding: This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Lung Cancer Research Program under Award No.W81XWH-15-2-0063. Atezolizumab was provided by Genentech. Institutional Support was provided by the UC Davis Comprehensive Cancer Center Support Grant NCI P30CA093373. AMM and LVV received support through NIH/NCI R01 CA240751. H.M.M. received support through NIH/NCI 4R00CA256526. Role of the funding source: These funding sources had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.